Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Breast cancer drug showdown: which one spares your memory?

NCT ID NCT00893061

Knowledge-focused Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 3 study looked at how four different hormone therapies (anastrozole, exemestane, letrozole, and tamoxifen) affect memory in postmenopausal women with breast cancer. The 44 participants took one of these drugs for 6 to 12 months, and researchers tested their verbal memory and other thinking skills. The goal was to find out which treatment has the least impact on memory, helping women and their doctors make more informed choices.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
anastrozole, exemestane, letrozole, tamoxifen citrate
What this could lead to
If successful, this study could help doctors choose breast cancer treatments that are less likely to cause memory problems.
What could go wrong
This is a small, completed study with only 44 participants, so results may not apply to all women. It only measured short-term memory changes over 6-12 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

44 people

The number who actually took part.

Started

Mar 2009

Finished

Nov 2014

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

DISEASE CHARACTERISTICS: * Histologically confirmed breast cancer * No metastatic disease * Meets criteria for initiating adjuvant endocrine therapy * Hormone receptor status: * Estrogen receptor- and/or progesterone receptor-positive disease PATIENT CHARACTERISTICS: * Postmenopausal, defined as no menstruation for ≥ 1 year, confirmed by a measurement of FSH and 17-beta-estradiol * Karnofsky performance status 80-100% * Native speaker of French * Beneficiary of a French Social Security insurance plan * No prior cognitive disorders * No depression or other confirmed active psychiatric disease * Able to undergo the medical monitoring of the trial due to geographic, social or psychological reasons * No personal or family history of thromboembolic disease PRIOR CONCURRENT THERAPY: * No prior adjuvant chemotherapy * No concurrent follow-up participation on another study * No concurrent treatment with psychotropic substances (i.e., long half life benzodiazepines, antipsychotics, anticholinesterase)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • Centre Eugene Marquis

    Rennes, France

  • Centre Oscar Lambret

    Lille, 59020, France

  • Centre Paul Strauss

    Strasbourg, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.